Ho, A. D. and Del Valle, F. and Haas, R. and Engelhard, M. and Hiddemann, W. and Rückle, H. and Schlimok, G. and Thiel, E. and Andreesen, Reinhard and Fiedler, W. (1990) Sequential studies on the role of mitoxantrone, high-dose cytarabine, and recombinant human granulocyte-macrophage colony-stimulating factor in the treatment of refractory non-Hodgkin's lymphoma. Seminars in oncology 17 (6 Suppl 10), 14-8; discussion 18.
Full text not available from this repository.
Mitoxantrone (Novantrone, American Cyanamid Company; NO) and high-dose cytarabine (Ara-C; AC) have each been shown to be active in non-Hodgkin's lymphomas (NHL) in various studies. The studies reported here are sequential. The first study (NOAC I) combined high-dose cytarabine (3 g/m2/12 h as a 3 h infusion on day 1) with mitoxantrone (10 mg/m2/d on days 2 and 3). Of 31 patients with relapsed and ...
Export bibliographical data
|Institutions:||Medicine > Abteilung für Hämatologie und Internistische Onkologie|
|Subjects:||600 Technology > 610 Medical sciences Medicine|
|Refereed:||Yes, this version has been refereed|
|Created at the University of Regensburg:||Yes|
|Deposited On:||14 Apr 2010 05:30|
|Last Modified:||14 Apr 2010 05:30|